MedTrace Logo

Time Spent In Target Glucose Range in Women With T2D Diabetes in Pregnancy

NCT06147466 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-03-20

No results posted yet for this study

Summary

Prospective cohort study to determine to what extent women with type 2 diabetes are achieving the time in the target range outlined for women with type 1 diabetes (70-140 mg/dl or 3.5-7.8 mmol/l), overall and by trimester, by standard CGM measures and functional data analysis

Conditions

  • Diabete Type 2
  • Pregnancy in Diabetic

Interventions

DEVICE

Dexcom Continuous Glucose Monitoring

A continuous glucose monitor (CGM) is a wearable device that tracks blood glucose (sugar) every few minutes, throughout the day and night. The readings are relayed in real time to a device which can be read by the patient, caregiver or health-care provider, even remotely

Sponsors & Collaborators

  • University of Manitoba

    collaborator OTHER

  • Women's College Hospital

    collaborator OTHER

  • Mount Sinai Hospital, Canada

    lead OTHER

Principal Investigators

  • Denice Feig · Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-01
Primary Completion
2026-03-01
Completion
2026-06-01
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06147466 on ClinicalTrials.gov